Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 12, 2019Heart Failure ReviewsOpen Access

Angiotensin receptor/neprilysin inhibitor—a breakthrough in chronic heart failure therapy: summary of subanalysis on PARADIGM-HF trial findings

View Full Paper
Ask AI
Bookmark
Share

Why the study?

To summarise current knowledge on the activity of ARNI in selected groups of patients with HFrEF based on recent PARADIGM-HF subanalyses and findings from the TRANSITION study.

Does ARNI therapy improve outcomes across various clinical subgroups and settings in patients with HFrEF?

Design

Narrative review

Authors

MKMarcin KsiążczykMLMałgorzata Lelonek

Discussion

Loading...

Member takes

Overview

ARNI-device co-use in optimized HFrEF may be feasible; leaves open dedicated interaction trials.

Structured PICO

Does ARNI therapy improve outcomes across various clinical subgroups and settings in patients with HFrEF?

P
Population
Patients with heart failure with reduced ejection fraction (HFrEF), including subgroups with and without chronic kidney disease, diabetes, and acute decompensated heart failure
I
Intervention
Angiotensin receptor/neprilysin inhibitor (ARNI)
C
Comparator
ACEI (enalapril) or ACEI/ARB naïve

This review highlights the broad clinical benefits of ARNI in various HFrEF subpopulations and supports its safe initiation even after acute decompensation.

Cite This Study

Książczyk et al. (2019) studied this question.

synapsesocial.com/papers/6a7155cb26770c2b8de10abbhttps://doi.org/10.1007/s10741-019-09879-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan2016 · 182 citations
  2. 2Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients2015 · 421 citations
  3. 3Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure2014 · 6,987 citations
  4. 4Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure2018 · 457 citations
  5. 5A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure2001 · 3,117 citations